Clinical Trial Update: Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating D9421-C at 9 mg and 15 mg versus placebo in Japanese patients with active Crohn's disease; efficacy and safety results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• D9421-C

Snippet

Sponsor: AstraZeneca | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2012-02-24